201 related articles for article (PubMed ID: 2874738)
1. A double-blind study comparing an acellular pertussis-component DTP vaccine with a whole-cell pertussis-component DTP vaccine in 18-month-old children.
Lewis K; Cherry JD; Holroyd HJ; Baker LR; Dudenhoeffer FE; Robinson RG
Am J Dis Child; 1986 Sep; 140(9):872-6. PubMed ID: 2874738
[TBL] [Abstract][Full Text] [Related]
2. Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children.
Morgan CM; Blumberg DA; Cherry JD; Reisinger KS; Blatter MM; Blumer JL; Dekker CL; Stout MG; Christenson PD
Am J Dis Child; 1990 Jan; 144(1):41-5. PubMed ID: 2403747
[TBL] [Abstract][Full Text] [Related]
3. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants.
Anderson EL; Belshe RB; Bartram J
J Infect Dis; 1988 Apr; 157(4):731-7. PubMed ID: 2894399
[TBL] [Abstract][Full Text] [Related]
4. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children.
Pichichero ME; Badgett JT; Rodgers GC; McLinn S; Trevino-Scatterday B; Nelson JD
Pediatr Infect Dis J; 1987 Apr; 6(4):352-63. PubMed ID: 3495775
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.
Marcinak JF; Ward M; Frank AL; Boyer KM; Froeschle JE; Hosbach PH
Am J Dis Child; 1993 Mar; 147(3):290-4. PubMed ID: 8438810
[TBL] [Abstract][Full Text] [Related]
6. Clinical and serologic responses to acellular pertussis vaccine in infants and young children.
Anderson EL; Belshe RB; Bartram J; Gurwith M; Hung P; Levner M; Vernon SK
Am J Dis Child; 1987 Sep; 141(9):949-53. PubMed ID: 3618569
[TBL] [Abstract][Full Text] [Related]
7. Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components.
Edwards KM; Lawrence E; Wright PF
Am J Dis Child; 1986 Sep; 140(9):867-71. PubMed ID: 3526866
[TBL] [Abstract][Full Text] [Related]
8. Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody.
Blumberg DA; Mink CM; Cherry JD; Reisinger KS; Blatter MM; Congeni BL; Dekker CL; Stout MG; Mezzatesta JR; Scott JV
J Pediatr; 1990 Jul; 117(1 Pt 1):46-51. PubMed ID: 2196360
[TBL] [Abstract][Full Text] [Related]
9. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children.
Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S
Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132
[TBL] [Abstract][Full Text] [Related]
10. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
Bernstein HH; Rothstein EP; Pichichero ME; Francis AB; Kovel AJ; Disney FA; Green JL; Marsocci SM; Lynd AM; Wood GC
Am J Dis Child; 1992 May; 146(5):556-9. PubMed ID: 1621656
[TBL] [Abstract][Full Text] [Related]
11. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
12. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
13. Comparison of acellular (B type) and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines as the first booster immunization in 15- to 24-month-old children.
Feldman S; Perry S; Andrew M; Jones L; Moffitt JE
J Pediatr; 1992 Dec; 121(6):857-61. PubMed ID: 1447645
[TBL] [Abstract][Full Text] [Related]
14. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults.
Halperin SA; Smith B; Russell M; Hasselback P; Guasparini R; Skowronski D; Meekison W; Parker R; Lavigne P; Barreto L
Vaccine; 2000 Jan; 18(14):1312-9. PubMed ID: 10618527
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
[TBL] [Abstract][Full Text] [Related]
16. [The immunological basis of the administration of DTP-polio vaccine].
Cohen H
Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905
[TBL] [Abstract][Full Text] [Related]
17. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
18. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
[TBL] [Abstract][Full Text] [Related]
19. Comparison of a diphtheria and tetanus toxoids and bicomponent acellular pertussis vaccine with diphtheria and tetanus toxoids and whole-cell pertussis vaccine in infants.
Pichichero ME; Francis AB; Marsocci SM; Green JL; Disney FA
Am J Dis Child; 1993 Mar; 147(3):295-9. PubMed ID: 8438811
[TBL] [Abstract][Full Text] [Related]
20. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
